Glaukos Corp（GKOS）股票分析GKOSGlaukos Corp

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Glaukos Corp (GKOS) is a good buy right now due to its current price of $178.88, which is well below the average analyst price target of $205, suggesting significant upside potential. Additionally, the stock has shown a strong year-to-date change of +61.56% and a one-year change of +136.36%, indicating robust growth momentum. However, the main risk is the negative net income reported in the latest quarter, which was -$18,377,000, reflecting ongoing challenges in profitability. Overall, the strong revenue growth and positive analyst sentiment outweigh the risks, making it a favorable investment opportunity for long-term investors.

10 analysts cover GKOS: 10 rate it Buy, 0 Hold and 0 Sell. The average price target is 127.08.